On July 28, 2011, the Board of Directors of Samsung Electronics authorized a capital investment of KRW 90 billion to participate in Samsung Biologics rights offering. Samsung Biologics will use the fund raised from the rights offering to construct a new biopharmaceutical production line. In April 2011, Samsung Electronics funded 40% (KRW 30 billion) of the initial capital of Samsung Biologics. Under the rights issue, Samsung Electronics will purchase shares in proportion to its current 40% stake in Samsung Biologics, and pay KRW 90 billion in three equal installments. •First installment (September 2011): KRW 30 billion •Second installment (January 2012): KRW 30 billion •Third installment (April 2012): KRW 30 billion